- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced that it has closed $5.3 million of an anticipated $11 million Series C funding round. This first portion closed on April 30, with the balance expected within the next 60 to 90 days.
"Our technology has been proven for biomarker discovery through hundreds of studies with many industry-leading partners. As a result, our service business has been very successful and continues to grow," said John Ryals, chief executive at Metabolon. "Our Series C funding will help to launch our diagnostics business with exciting products in prostate cancer and insulin resistance."
Metabolon offers global biochemical profiling (metabolomic) services to researchers working in drug safety and toxicology, bioprocess optimization, consumer products and other areas which benefit from insight into complex biochemical processes and how they change in response to experimental variables.
The company's technology has been used to identify biochemical biomarkers useful for the development of a wide range of diagnostics. These markers are being applied to the development of its own proprietary diagnostic tools for insulin resistance and prostate cancer*. Metabolon also offers research tools based on these biomarkers for investigators.
About Metabolon, Inc.
Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization.
For more information, please click here
800 Capitola Drive, Suite 1
Durham, NC 27713
Copyright © Metabolon, Inc.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Forge Nano 2017: 1st Quarter Media Update April 20th, 2017
Harris & Harris Group Issues Its Financial Statements as of December 31, 2016, Posts Its Annual Shareholder Letter, And Will Host a Conference Call for Shareholders on Friday, March 17, 2017 March 15th, 2017